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Abstract
Backgrounds: Adiponectin is an adipose tissue-derived mediator with significant anti-atherogenic
properties. A few studies were done in acute phase of myocardial infarction especially in non obese
patients. We design a study to investigate the association between adiponectin concentration and
acute phase of myocardial infarction in non obese patients.
Methods: This case-control study was done in Paymaneah Hospital (Jahrom, Iran) from Feb 2007
to May 2008. Plasma adiponectin levels were measured in 43 patients with AMI (mean age: 62.7 ±
13.3 years, male: 67.4%) at the first 24 hours of admission and 43 normal controls (mean age: 62.1
± 12.3 years, male: 55.8%) matched for age, sex and other CAD risk factors.
Results: Adiponectin levels in patients with AMI (3.36 μg/mL) were significantly lower than that of
the control group (5.03 μg/mL) (p < 0.0001). Lower adiponectin were independently associated
with higher risk of AMI (odds ratio = 8.97; 95% CIs: 2.3–34.5; p = 0.001). Adiponectin levels
negatively correlated with triglyceride (r = -0.46, p = 0.002) and total cholesterol (r = -0.32, p =
0.03) in the case group and with body mass index (BMI) in control subjects.
Conclusion: The present study showed that adiponectin was associated with AMI in non obese
patients but it is not related to sex, age and other CAD risk factors.
Introduction
Adiponectin is a new member of adipocyte derived pro-
teins belonging to the soluble defense collagens that pro-
duces specifically by adipose tissue and is present in the
circulation [1]. Lower levels of plasma adiponectin have
been detected in obesity [1], Type 2 diabetes mellitus [2]
and coronary artery disease (CAD) [3]. Adiponectin
appears to play an important role in glucose and lipid
metabolism, vascular biology, and energy homeostasis
[4,5] and low adiponectin level has been shown as a risk
factor for cardiovascular events [6,7].
Although several studies have been done on adiponectin
and CAD, but most of them have been conducted on
patients with chronic ischemia and the studies in acute
phase of myocardial infarction (MI) especially in develop-
ing countries are limited and rare [8-14]. Yet there is con-
troversy about the association of adiponectin and sex
[8,11], CAD risk factors [8,11,14] and race [13]. Although
adiponectin decreased in both obesity and AMI, some
study [9] considered this for explanation of obesity effect
on AMI, but with attention to direct effect of adiponectin
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mia in AMI is independent of obesity.
The purpose of present study was to investigate the associ-
ation between plasma adiponectin levels and AMI in Ira-
nian non obese patients.
Methods
Subjects
This case-control study conducted on 43 consecutive
patients with acute myocardial infarction (AMI) (as case
group) including 29 men and 16 women with the mean
age of 62.72 ± 13.4 y/o out of 850 patients who were
referred with chest pain to emergency room at Paymaneah
Hospital, a referral center affiliated to Jahrom Medical
University (Iran) from Feb 2007 to May 2008. We selected
all patients after approved diagnosis of AMI and rule out
of other patients with exclusion criteria. We also selected
43 individuals with atypical chest pain and normal coro-
nary angiography as control group and matched them
with case group for age, sex and other CAD risk factors
such as hypertension (HTN), diabetes mellitus (DM),
hyperlipidemia (HLP), body mass index (BMI), smoking
and renal function.
The study protocol was approved by research ethics com-
mittee of Jahrom Medical University and informed con-
sent was obtained from all participants before enrollment.
A questionnaire including information about the past
medical and drug history (HTN, HLP, DM, smoking,
chronic diseases such as rheumatologic disorder, renal
failure and asthma), family history of CAD and demo-
graphic information was completed for each subjects.
The exclusion criteria were the history of infectious dis-
eases, collagen vascular disease such as systemic lupus ery-
thematous, scleroderma, rheumatoid arthritis, cirrhosis,
hepatitis, renal disease, malignancy, septicemia, angi-
oplasty and stable or unstable angina.
Definitions
AMI was defined as resting chest pain lasting more than
30 minutes accompanied by ischemic electrocardio-
graphic changes and was confirmed by the presence of
total creatine kinase or creatine kinase isoenzyme (CK-
MB) fraction levels of more than twice the upper normal
limit. We considered ST elevation MI (STEMI) according
to ST segment elevation > 1 mm in two neighbor electro-
cardiographic leads and non ST elevation MI (NSTEMI)
without this finding [16]. The absence of any narrowing
in coronary artery diameter was considered as normal cor-
onary angiography. Unstable angina was defined as
angina pectoris (or equivalent type of ischemic discom-
fort) with at least one of three features: occurring at rest
(or minimal exertion) and usually lasting > 20 minutes (if
not interrupted by nitroglycerin administration); being
severe and described as frank pain, and of new onset (i.e.,
within 1 month; and occurring with a crescendo pattern
(i.e., more severe, prolonged, or frequent than previously)
[17]. Height and weight were measured with light clothes
and without shoes using a stadiometer and electronic
scale in the cardiac care unit after confirming patient sta-
ble condition. Body mass index was calculated [weight
(kg)/height (m)2] and used as the criteria of overall adi-
posity. We defined BMI less than 25 as normal, 26–30 as
overweight and above 30 as obese [18]. Blood pressure
was measured two times in sitting position after 5 min of
rest using a mercury sphygmomanometer (Riester, Ger-
many). Hypertension was defined as blood pressure more
than 130/85 mmHg or use of any antihypertensive medi-
cation [19]. Diabetes mellitus was defined by a physi-
cian's diagnosis, a fasting plasma glucose level of ≥ 126
mg/dl or use of diabetes medications [20]. All subjects
completed a research questionnaire on smoking habits.
Laboratory analysis
Fasting levels of plasma total cholesterol, high density
lipoprotein cholesterol (HDL), low density lipoprotein
cholesterol (LDL), and triglycerides were determined in
Research Laboratory of Jahrom Medical University. Total
cholesterol and triglyceride levels were measured by enzy-
matic techniques using an Selectra E biochromatic ana-
lyzer. HDL and LDL level was measured after precipitation
of the other lipoproteins with heparin and manganese
chloride (Human, Germany). Plasma glucose levels were
measured by the glucose oxidase method and serum cre-
atinine by the Jaffe reaction method.
Blood samples (5 cc) for adiponectin were obtained by
venipuncture from the patients immediately after admis-
sion before starting any IV medication by trained staff and
for lipid profile and fasting blood sugar at the first 24
hours of AMI after 12 hours of fasting. In control subjects
all blood sample were obtained after 12 hours of fasting
then plasma was separated and frozen at -70°C for later
processing. Then we determined the plasma adiponectin
concentration by enzyme linked immunosorbent assay
(ELISA) (Biovendor Laboratory Medicine, Inc., Brno,
Czech Republic) (REF: RD195023100) in patients and
control group. This assay measures the total adiponectin
that is all molecular forms. The sensitivity and the intra-
and interassay coefficients of variation were 0.8 mg/liter,
6% and 7%, respectively.
Statistical analysis
Statistical analysis was performed by SPSS (version 11.5;
SPSS, Inc., Chicago, IL). Data were expressed as mean ± 1
SD. Continuous variables were summarized as mean ± SD
and compared using Student's t-test. Discrete variablesPage 2 of 6
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Nominal variables were tested with Pearson's χ2 test and
Binary variables were tested with the Mann-whitney test.
Pearson correlation coefficients were calculated to evalu-
ate unadjusted (univariate) associations between adi-
ponectin and other variables. All tests were two-tailed
with a 0.05 type I error rate. Logistic regression models
were used to estimate odds ratios (ORs) between three dif-
ferent adiponectin levels and AMI. We considered adi-
ponectin level greater than 5 μg/ml as reference level.
Results
The demographic and clinical characteristics of the study
groups, as well as laboratory variables are shown in Table
1. In patient group 6 cases (14%) had non-ST elevation MI
(NSTEMI) and 37 (86%) had ST elevation MI (STEMI).
Plasma adiponectin levels in the patients with AMI on
admission were significantly lower than those in the con-
trol group (3.3 ± 1.7 μg/ml vs. 5 ± 1.5 μg/ml, p < 0.001).
We examined the association between plasma adiponec-
tin levels and selected cardiovascular risk factors among
cases and controls. There was a significant negative corre-
lation between plasma adiponectin levels and triglyceride
(r = -0.46, p = 0.002) and total cholesterol (r = -0.33, p =
0.03) in the case group as well as BMI in control group (r
= -0.44, p = 0.003). No significant correlation was found
between HTN, Type 1 DM, Type 2 DM, age, sex, smoking,
serum creatinine, LDL and HDL and adiponectin levels
(Table 2). There was no significant difference in plasma
adiponectin between patients with STEMI and NSTEMI
(3.4 ± 1.7 μg/ml vs. 3 ± 1.5 μg/ml, p = 0.49).
Patients were divided into three groups based on adi-
ponectin split level. The results are shown in Table 3. The
group with the adiponectin levels greater than 80th per-
centile (5 μg/mL) was used as the reference. Odds ratio for
AMI increased with decreasing adiponectin levels. Lower
adiponectin were independently associated with higher
risk of AMI (odds ratio = 8.97; 95% CIs: 2.3–34.5; p =
0.001). The greatest increase in AMI risk was seen at adi-
ponectin levels ≤ 3 μg/mL.
Discussion
In the present case-control study, in line with previous
studies [7-10,21], we found that lower plasma adiponec-
tin levels was associated with AMI among Iranian non
obese patients independent of traditional cardiovascular
risk factors. Of note, the relationship was also independ-
ent of hypertension, diabetes, age, sex, BMI and smoking;
the factors that were closely related to adiponectin levels
in previous studies [10].
Cavusoglu et al. [22] showed that high baseline plasma
adiponectin levels are independently associated with an
increased risk of both death and MI at 2-year follow-up in
a cohort of men with stable angina, unstable angina, and
non ST elevation MI referred for coronary angiography.
Our study also showed significant association between
adiponectin levels in patients with ST elevation MI and
non-ST elevation MI in spite of their different pathophys-
iology [23,24]. These findings indicated that adiponectin
may be directly involved in the pathophysiology of
atherosclerosis and thrombosis at the vascular wall level.
The exact mechanism of adiponectin decrease immedi-
ately after the onset of AMI remains unknown. Although
some authors [25] believed that the changed adiponectin
levels are associated with presence of risk factors of meta-







Age 62.7 ± 13.3 62.1 ± 12.3 0.84
Male, n (%) 29 (67.4%) 24 (55.8%) 0.27
BMI (kg/m2) 22.3 ± 3 23.6 ± 3.15 0.44
Current smoker, n(%) 10 (23.3%) 4 (9.3%) 0.14
HTN, n(%) 9 (20.9%) 14 (32.6%) 0.33
Adiponectin (μg/mL) 3.3 ± 1.7 5 ± 1.5 < 0.001*
Type 1 DM, n (%) 2 (4.7%) 4(9.3%) 0.68
Type 2 DM, n (%) 7(16.3%) 4(9.3%) 0.52
Total Cholesterol (mg/dL) 189.3 ± 45.2 171.8 ± 33 0.05
LDL-C (mg/dL) 113.7 ± 36.6 103.9 ± 28.7 0.13
HDL-C (mg/dL) 46.7 ± 11.4 41.9 ± 9.5 0.05
LDL/HDL ratio 4.23 4.24 0.96
Triglyceride (mg/dL) 146 ± 99.6 144 ± 99.8 0.93
Serum creatinine (mg/dl) 1 ± 0.1 1.1 ± 0.1 0.68
BMI: body mass index, LDL-C: low density lipoprotein- cholesterol, 
HDL-C: high density lipoprotein- cholesterol, BUN: blood urea 
nitrogen
Values are presented as mean ± SD or %.
Table 2: Pearson Correlation Coefficients between Plasma 
Adiponectin Level and selected variables in the Case and 
Control groups
Variable Case group Control group
Correlation P-value Correlation P-value
Age 0.24 0.04* 0.04 0.79
BMI -0.03 0.86 -0.44 0.003**
Serum creatinine 0.13 0.41 0.27 0.08
Total Cholesterol -0.33 0.03* -0.11 0.48
LDL-C -0.03 0.84 -0.02 0.87
HDL-C -0.06 0.72 -0.09 0.55
Triglyceride -0.46 0.002** -.09 0.57
TC/HDL -0.22 0.14 -0.40 0.80
*P < 0.05, **P < 0.001
BMI: body mass index, IDDM: insulin dependent diabetes mellitus, 
NIDDM: non insulin dependent diabetes mellitus, LDL-C: low density 
lipoprotein- cholesterol, HDL-C: high density lipoprotein- 
cholesterol, BUN: blood urea nitrogenPage 3 of 6
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emphasis that its deficiency may lead to thrombus forma-
tion and platelet aggregation [15]. Plasma adiponectin
may decrease as a result of rupture of coronary plaques.
Adiponectin has been detected in the injured vessels but
not in the intact ones in humans and rodents [26,27].
Although it seems that low adiponctin in AMI is second-
ary to plaque rupture and inflammation but if according
to previous cohort studies [14,22,28] adiponectin con-
sider as risk factor for coronary artery disease, measure-
ment of adiponectin levels may be helpful in the
stratification of patients at risk of AMI. In our study the
greatest increase in MI risk occurred at adiponectin levels
≤ 3 μg/mL in contrast to the Wolk et al. study [9] that this
rise occurred at adiponectin levels ≤ 5.5 μg/mL. This dif-
ference may be due to exclusion of the patients with major
CAD risk factors in Wolk et al. study that were not
excluded from us. Our present data, consistent with those
of other authors [8,11,14,22,25] showed that adiponectin
levels was negatively correlated with triglycerides in
patients and with BMI only in the control subjects, but in
contrast to the others we found negative correlation with
total cholesterol in patients and any correlation with
other CAD risk factors such as smoking[14], age, DM,
HTN, HDL and LDL.
About non significant correlation between plasma adi-
ponectin levels and BMI in case group, it should be noted
that in the most of previous studies [8,11,25,29] there
were significant but weak correlation (r = -0.18 to -0.33)
between them, So, in confirming Pliz et al opinion [11], it
should be noted that the adiponectin levels may be more
associated with blood lipid profile and insulin resistance
instead of obesity. Also this difference may be due to
reduction of adiponectin secondary to acute MI.
Most studies [8,10-12,14] showed higher adiponectin lev-
els in women in comparison to men but our results
showed no statistically significant difference in adiponec-
tin levels between men and women. Nakamura et al. [8]
found similar results but they believed that solid phase
ELISA was the reason for this difference, because this assay
cannot distinguish between the lower weight trimer-
dimer forms of adiponectin and the high molecular
weight complexes; one of the factors associated with sex
difference. We measured all forms of adiponectin and this
difference in our study is not related to this reason. It may
be due to less obesity in our subjects and/or mismatch
between BMI in men and women in other studies.
Another remarkable clinical finding in our study was that
plasma adiponectin levels in our study were much lower
than those of other studies [7-9,14] such that this level in
our normal subjects was approximately equal to that of
patients with AMI. This may be due to lower BMI in our
subjects, high carbohydrate diet [30] or race differences.
Kanaya et al. [13] showed that Whites had higher median
adiponectin levels than Blacks and high circulating levels
of adiponectin were associated with a higher risk of CAD
in older Blacks. Significant differences in our results indi-
cate that before application of adiponectin in clinical set-
ting, further prospective and cohort studies in other
countries and races are required to confirm our results.
Although some studies [30,31] showed increased adi-
ponectin level in patients with renal dysfunction but our
study showed as the same of Shibata et al. [32] that there
is no association between adiponectin and renal function
in atherosclerotic patients with normal renal function.
Study limitations
Serum adiponectin levels were measured in a single sam-
ple, which might limited the observed associations. Weak
or any correlation may be due to small number of partic-
ipants in this study. We didn't study the association of adi-
ponectin concentration with amount of smoking, diet
and previous medication because of limited data. Some
authors such as Inoue et al. [33] suggest that measurement
of high molecular weight (HMW) adiponectin alone may
be a clinically useful marker of CAD but we measured
only total form of adiponectin. Although abdominal
obesity can give better insight than BMI, but because some
studies use only BMI, for comparison we only used this
parameter too.
Conclusion
Lower plasma adiponectin levels are associated with AMI
in Iranian non obese patients, independent of other tradi-
tional cardiovascular risk factors. Our findings showed
Table 3: Odds ratio association of different adiponectin levels with acute myocardial infarction (AMI)
Adiponectin levels Case group (AMI) (n, %) Control group
(n,%)
P value OR (95% CI)
> 5 μg/mL 9 (20.9%) 19 (44.2%) Reference group (1.00)
3.01–5 μg/mL 17 (39.5.6%) 20 (46.5%) 0.26 1.97 (0.65–4.99)
≤ 3 μg/mL 17 (39.5%) 4(9.3%) 0.001* 8.97 (2.3–34.5)
CI: Confidence Interval, OR: odds ratio
*p < 0.001 significant with single logistic regression analysisPage 4 of 6
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this decreased in AMI is not related only to obesity.
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